Revolutionary products will eliminate catheter-associated urinary tract infections in hospitals and increase patient comfort while lowering health care costs
Ur24Technology Inc., a privately held medical device company, has launched the TrueClr catheter product line – offering physicians, nurses and patients a choice that will eliminate catheter-associated urinary tract infections in hospitals, increase patient comfort and quality of life, and lower health care costs.
The first external catheter designed to actively empty the bladder, the new latex-free TrueClr product line for adults and children will be showcased at Medica 2022, one of the world’s leading medical trade fairs, in Dusseldorf, Germany from Nov. 13-17.
Dr. Jon Meliones, M.D., FCCM, medical director at Ur24Technology, said: “I am convinced the TrueClr external catheters will fundamentally revolutionize medical practices. It’s an active elimination system vs. passive – the only catheter of its kind in the world.” Dr. Meliones will be a featured speaker at Medica 2022.
US data shows that internal catheters are associated with 80 percent of hospital-related urinary tract infections, which cost the health care system an estimated $450 million yearly. Nearly 13,000 deaths annually are related to internal catheters. Key features of the TrueClr product line include:
- Eliminates internal catheter-associated urinary tract infections
- Uses light, continuous section
- Non-invasive, non-adhesive, comfortable
- Leak proof design
- Avoids urine contact with skin
- Eliminates skin irritation and inflammation
- Portable & reusable – in hospitals or at home, with easy cleaning
- Covered under Medicare Part B, DME reimbursement
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the US and internationally, using its distribution network in 132 countries. The companies will jointly promote TrueClr, which will be co-branded, at Medica 2022.
Source: Company Press Release